Maxim Group began coverage on shares of BioLife Solutions Inc. (NASDAQ:BLFS) in a report issued on Thursday. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s target price points to a potential upside of 75.45% from the stock’s current price.
BioLife Solutions (NASDAQ:BLFS) opened at 1.7099 on Thursday. BioLife Solutions has a 52-week low of $1.43 and a 52-week high of $3.58. The firm has a 50-day moving average of $1.64 and a 200 day moving average of $1.75. The company’s market capitalization is $22.02 million.
BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. BioLife Solutions had a negative net margin of 59.91% and a negative return on equity of 57.51%. The business earned $2.10 million during the quarter, compared to analyst estimates of $2.20 million. Equities analysts predict that BioLife Solutions will post ($0.35) earnings per share for the current fiscal year.
About BioLife Solutions
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.